Experts has a new look! Let us know what you think of the updates.

Provide feedback

Scholarly Works

Phase II study of individualized sunitinib (SUN)...

Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.

Abstract

4514 Background: Higher SUN exposure is associated with better outcomes. Patients (pts) with minimum toxicity on the standard schedule do worse than pts needing dosing changes for toxicity. Methods: It was hypothesized that toxicity-driven dose/schedule individualization would improve the primary endpoint (PFS) from 8.5 (EFFECT trial) to 14 months (mo), with 99 pts required to detect this with 90% power and 2-sided alpha = 0.05. In a …

Authors

Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA

Volume

35

Pagination

pp. 4514-4514

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

May 20, 2017

DOI

10.1200/jco.2017.35.15_suppl.4514

Conference proceedings

Journal of Clinical Oncology

Issue

15_suppl

ISSN

0732-183X

Associated Experts

Sebastien Hotte

Professor, Faculty of Health Sciences

Labels

Fields of Research (FoR)

3211 Oncology and carcinogenesis

View published work (Non-McMaster Users)